{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-091674","form_type":"8-K","ticker":"TOVX","cik":"0000894158","company_name":"Theriva Biologics, Inc.","filed_at":"2026-08-06T12:10:35+00:00","discovered_at":"2026-08-06T12:15:00.361373+00:00","generated_at":"2026-08-06T12:15:27.143298+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Theriva Biologics doses first patient in VIRAGE2 Phase 2a trial of VCN-01 in metastatic PDAC","bullets":["First patient dosed in VIRAGE2 Phase 2a trial evaluating more frequent repeated dosing of VCN-01 in first-line metastatic PDAC.","Enrollment completion expected H2 2026; initial pharmacodynamic and safety/tolerability data anticipated by Q3 2027.","Trial based on VIRAGE Phase 2b data where 2 doses of VCN-01 + SoC showed improved overall survival, progression-free survival, and duration of response vs SoC alone.","EMA and FDA feedback recognized potential of repeated VCN-01 dosing to improve clinical outcomes.","Results will inform dosing regimen for potential future pivotal Phase 3 trial."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-091674","json":"https://secwatch.observer/filing/0001104659-26-091674.json","markdown":"https://secwatch.observer/filing/0001104659-26-091674.md","text":"https://secwatch.observer/filing/0001104659-26-091674.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/894158/000110465926091674/0001104659-26-091674-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/894158/000110465926091674/tm2622359d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T12:15:27.143298+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}